Phase 1 Non-Alcoholic Fatty Liver Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 64 years old
- Your body weight falls within a healthy to moderately obese range (BMI between 18 and 44.9)
- You have been diagnosed with Type 2 diabetes according to 2021 American Diabetes Association guidelines
- You have been diagnosed with a liver condition called NAFLD (a build-up of fat in the liver not caused by alcohol)
- If you are able to have children, you must be willing to use contraception during the study
- If you are a woman who could become pregnant, you must have a negative pregnancy test before joining
- Your kidney function is within an acceptable range based on blood test results (confirm with trial site)
- You are able to follow all study requirements and attend appointments as needed
- You have signed a consent form agreeing to take part
Who may not be able to join:
- Your diabetes is not well controlled
- You have a serious ongoing illness that affects your ability to carry out everyday activities
- You currently drink significant amounts of alcohol, or have done so in the past
- Your blood fat (triglyceride) levels are very high (above 500 mg/dL)
- Your LDL ("bad") cholesterol levels are very high (above 190 mg/dL)
- Certain liver-related blood test results are significantly above the normal range (confirm with trial site)
- Your long-term blood sugar control measurement (HbA1c) is above 10.5%
- Your fasting blood sugar level is above 240 mg/dL
- Your platelet count (cells that help blood clot) is below a certain level
- You take medications known to be linked to NAFLD or that can harm the liver
- You take vitamin E supplements above 400 IU per day, or herbal supplements that may affect NAFLD
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Andrew Keates, PhD, 1Globe Health Institute
Phone: 617-649-1157
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Recommended Phase 2 Dose (RP2D)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.